United Therapeutics
S&P 400
$601.32
+0.87%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Comfortable interest cover: operating profit covers interest about 76.5 times.
- Return on equity is healthy at 20.9%.
- Return on capital employed is healthy at 22.4%.
- Net profit margin is strong at 41.9%.
- Current assets comfortably cover current liabilities (current ratio 6.6).
!Watch-points
No notable watch-points flagged by the automated checks.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreSafe zone
25.08
In Altman’s original study, companies in this range showed a low incidence of financial distress.
Piotroski F-ScoreModerate
6 / 7
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 7 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap$25.79B
Current Price$ 601.32
High / Low$ 609.99 / 430.02
Stock P/E21.315845
Book Value$ 139.74
Dividend Yield0%
ROCE22.41%
ROE20.85%
Current Ratio6.60
P/B Ratio4.0095754
EPS$ 27.86
PAT Margin41.94%
Cash PAT$1.42B
ICR76.54